Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION
2024-519521-37-01Phase 3Authorised
- Sponsor
- CORXEL Pharmaceuticals
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing JX10 with Placebo (2 arms). Primary endpoints: Efficacy: proportion with no or minimal symptoms at 90 days and Safety: symptomatic intracranial hemorrhage within 36 hours. Planned start Jul 2025; status: authorised.
02
Drugs
JX10
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2024-519521-37-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519521-37-01.